NCT03660839View on ClinicalTrials.gov

Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

September 11, 2018

Primary Completion Date

November 6, 2019

Study Completion Date

November 6, 2019

Conditions
Plasmodium Falciparum Infection
Interventions
DRUG

Artefenomel (OZ439)

Pharmaceutical form: Granules for oral suspension Route of administration: Oral

DRUG

Ferroquine (SSR97193)

Pharmaceutical form: Capsule Route of administration: Oral

Trial Locations (7)

Unknown

Investigational Site Number 2040001, Cotonou

Investigational Site Number 8540002, Banfora

Investigational Site Number 2660002, Lambaréné

Investigational Site Number 4040002, Siaya

Investigational Site Number 8000001, Tororo

01 BP218

Investigational Site Number 8540001, Ouagadougou

B.P. 4009

Investigational Site Number 2660001, Libreville

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
collaborator

Medicines for Malaria Venture

OTHER

lead

Sanofi

INDUSTRY

NCT03660839 - Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria | Biotech Hunter | Biotech Hunter